The NDA is supported by data from a clinical trial that compared the absorption and efficacy of the nasal treatment with oral and IV bumetanide in 68 healthy adults.
The updated labeling for Qelbree provides additional information on the pharmacodynamic profile of the drug. Findings show ...
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...
(HealthDay News) — There is considerable uncertainty regarding the effects of puberty blockers in young individuals experiencing gender dysphoria (GD), according to two reviews published online Jan.
Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.